aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obesity
Conditions
Obesity, Overweight, Chronic Weight Management
Trial Timeline
Dec 20, 2024 → Dec 1, 2025
NCT ID
NCT06703021About aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo
aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo is a phase 2 stage product being developed by Structure Therapeutics for Obesity. The current trial status is active. This product is registered under clinical trial identifier NCT06703021. Target conditions include Obesity, Overweight, Chronic Weight Management.
What happened to similar drugs?
20 of 20 similar drugs in Obesity were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06703021 | Phase 2 | Active |
Competing Products
20 competing products in Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MK0493 | Merck | Phase 2 | 35 |
| MK0557 | Merck | Phase 3 | 40 |
| AMG 786 | Amgen | Phase 1 | 29 |
| Bimagrumab + Tirzepatide + Bimagrumab Placebo + Tirzepatide Placebo | Eli Lilly | Phase 2 | 39 |
| Tirzepatide | Eli Lilly | Phase 2 | 42 |
| exenatide + Placebo | Eli Lilly | Approved | 43 |
| Brenipatide | Eli Lilly | Phase 1 | 36 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 47 |
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 32 |
| MBX 4291 + Placebo | MBX Biosciences | Phase 1 | 30 |
| PG-102 | Rani Therapeutics | Phase 1 | 26 |
| Orforglipron + Placebo | Eli Lilly | Phase 1 | 29 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 40 |
| Eloralintide + Placebo | Eli Lilly | Phase 1 | 29 |
| Oral Azelaprag (BGE-105) + Oral Placebo for Azelaprag (BGE-105) + Tirzepatide + Tirzepatide Placebo | Eli Lilly | Phase 2 | 27 |
| LY3437943 + Midazolam + Warfarin + Caffeine | Eli Lilly | Phase 1 | 29 |
| Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection | Skye Bioscience | Phase 2 | 29 |
| Tirzepatide | Eli Lilly | Approved | 50 |
| Adenosine + Regadenoson | Astellas Pharma | Pre-clinical | 26 |
| Micafungin + Micafungin | Astellas Pharma | Approved | 43 |